Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep;30(9):1228–1242. doi: 10.1101/gr.252106.119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Lopez et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 6. — SHANK2 reduces cell growth and promotes differentiation in neuroblastoma cell line models. (A–C) Western blots confirming overexpression of SHANK2 in all tested neuroblastoma cells: (A) SY5Y, (B) Be(2)C, (C) NGP. (D–F) Decreased proliferation in all three lines overexpressing SHANK2 (red) compared to controls (green), as measured by RT-CES. (G–I) Decreased viability in SHANK2 overexpressing cells (red) versus controls (green) as measured by ATP-dependent CellTiter-Glo Assay. (J,K) IncuCyte images of Be(2)C cells for vector control (J) and SHANK2-expressing cells (K) at 78 h post treatment with 1 µM ATRA. Neurite extensions masked in pink; cell bodies masked in blue. (L) Neurite length normalized to cell body area starting immediately after ATRA application corresponding to Be(2)C cells images at different time points. (M,N) SY5Y images from IncuCyte at day nine post ATRA treatment (5 µM). (O) Neurite outgrowth normalized to cell body area in corresponding to SY5Y cells images at different time points.